Diadema Partners LP Summit Therapeutics Inc. Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
A detailed history of Diadema Partners LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Diadema Partners LP holds 932 shares of SMMT stock, worth $16,841. This represents 0.01% of its overall portfolio holdings.
Number of Shares
932
Previous 24,700
96.23%
Holding current value
$16,841
Previous $476 Million
95.84%
% of portfolio
0.01%
Previous 0.12%
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
270Shares Held
90.5MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$609 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$206 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$143 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$72.6 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$70.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...